Pharma deal value rises 55.2% in July 2026: GlobalData

The healthcare industry reported 87 deals worth $29.5 billion in July 2026, compared with the last 12 months’ average of 85 deals worth $29.6 billion, according to GlobalData. Deal value increased by 55.2 per cent in July 2026 compared with July 2025.

Vertex Pharmaceuticals Inc agreed to acquire Crinetics Pharmaceuticals Inc, a pharmaceutical company focused on developing therapies for endocrine diseases, for $85 per share in cash, representing a total enterprise value of approximately $9.8 billion.

Eli Lilly and Company agreed to acquire AtaiBeckley Inc, a clinical-stage biopharmaceutical company developing therapeutics for mental health conditions, for up to $3.8 billion.

Apollo Global Management agreed to obtain a minority stake in Bayer’s long-acting reversible contraceptives (LARC) business for $3.4 billion. These were the three major deals reported in July 2026.

Venture capital funding decreased by 6.4 per cent in July 2026 compared with July 2025. The healthcare industry reported 83 venture capital (VC) deals worth $2.3 billion in July 2026, compared with the last 12 months’ average of 114 deals worth $3.3 billion.

Chai Discovery Inc raised $400 million in a Series C financing round to build AI models to accelerate pre-clinical drug discovery by predicting and reprogramming the interactions between molecules.

AdvanCell Isotopes Pty Ltd, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, raised $315 million in a Series D financing round to advance its lead therapy ADVC001 towards registrational development.

Celea Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing treatments for people with serious respiratory diseases, raised $180 million in financing to execute its strategy of unlocking the full potential of deupirfenidone for patients. These were the three major VC deals reported in July 2026.